Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% despite missing revenue forecasts in its latest quarterly report, with revenues of US$7.7m falling 41% short of expectations. Analysts have subsequently cut 2026 revenue estimates by a substantial amount to US$52.3m, although loss per share estimates remain …